Midazolam Doses for Premedication, anxiolysis,Sedation

Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
I now have comprehensive data from multiple authoritative anesthesia textbooks. Here is the full synthesis:

Midazolam — Doses for Premedication, Anxiolysis & Sedation

Mechanism & Clinical Profile

Midazolam is a water-soluble benzodiazepine that undergoes conformational change at physiological pH, becoming highly lipophilic. It acts as a GABA-A receptor agonist, augmenting chloride channel opening frequency. Key clinical effects:
  • Anxiolysis
  • Anterograde amnesia (retrograde memory unaffected)
  • Sedation / hypnosis
  • Anticonvulsant
  • Minimal cardiovascular and respiratory depression (at clinical doses)
  • Reversible with flumazenil
Peak IV effect: 2–3 minutes | Elimination half-life: 1.8–4 hours

Dosing by Indication

1. Preoperative Premedication

RoutePopulationDoseNotes
OralAdults7.5–15 mgMost common oral dose range
IVAdults1–2.5 mg increments (titrated)Given within 1 hour of induction
IMAdults0.07–0.15 mg/kgWell-absorbed IM; peak in ~30 min
OralChildren0.5 mg/kg (max 15 mg)Sedation/anxiolysis within ~20 min
IntranasalChildren0.2–0.3 mg/kgEffective preoperative sedation
BuccalChildren0.07 mg/kg
SublingualChildren0.1 mg/kg
RectalChildren0.5 mg/kg
IVChildren0.05–0.1 mg/kg
Factors influencing dose: age, ASA physical status, level of anxiety, type and duration of surgery. Doses should be reduced in the elderly.

2. Anxiolysis (Prior to Regional or General Anesthesia)

RouteDoseNotes
IV0.05–0.1 mg/kg"Nearly ubiquitous" for preoperative anxiolysis before GA or regional
IV (incremental)~1–2 mg IV titratedStandard adult incremental anxiolytic dose

3. Procedural / Conscious Sedation

IndicationRouteDoseNotes
General procedural sedationIV0.01–0.1 mg/kg (titrated)Titrate to dysarthria or adequate sedation
Moderate sedation (surgical/diagnostic)IV0.02–0.04 mg/kg (~1–2 mg) bolusBarash Table 30-7: bolus prior to stimulus
CardioversionIV0.15 mg/kg (≥5 mg for average adult)Induction ~2 min after dose
Emergency sedationIV0.05 mg/kgPer Rosen's Emergency Medicine
Titration endpoint: adequate sedation or dysarthria. Onset rapid; time to peak effect 2–3 minutes IV. Duration is dose-dependent.

4. Anesthesia Induction

RouteDoseNotes
IV0.1–0.4 mg/kgHigher end for induction of general anesthesia
IV (Barash)0.1–0.3 mg/kgDuration of action 15–20 min

5. ICU Sedation (Infusion)

Midazolam infusions provide continuous sedation comparable to propofol; however, extubation and recovery time are shorter with propofol. The active metabolite (1-hydroxymidazolam) accumulates with prolonged infusions, extending duration. Context-sensitive half-time increases with infusion duration — a key limitation.

Dose Equivalence Comparison

DrugEquivalent Dose (mg)Oral Peak (h)Elimination t½ (h)
Diazepam101–1.520–40
Lorazepam1–22–410–20
Midazolam3–50.5–11–4

Pharmacokinetic Summary

ParameterValue
Volume of distribution1–3.1 L/kg
Protein binding94%
Clearance6.4–11 mL/kg/min
Redistribution half-life7–15 min
Elimination half-life1.8–2.6 h (mean ~3 h)
Active metabolite1-hydroxymidazolam (~20% potency)

Special Considerations

  • Elderly patients: Reduce doses — pharmacodynamic sensitivity is increased; elimination half-life may extend to 4 hours.
  • Hepatic/renal dysfunction: Clearance reduced; metabolite accumulates with infusions.
  • Synergism: Combination with opioids produces synergistic CNS depression; with ketamine, interaction is additive. Dose reduce both agents when combined.
  • Respiration: Minimal respiratory effects at clinical premedication doses, even up to 1.0 mg/kg (max 20 mg) in adults, but monitor when combined with other CNS depressants.
  • Pediatric advantage: Positive behavioral effects noted up to 1 week postoperatively with oral midazolam premedication.
  • Reversal: Flumazenil available for excessive sedation or respiratory depression.

Sources: Miller's Anesthesia 10e, p. 2528–2530 | Morgan & Mikhail's Clinical Anesthesiology 7e, p. 327 | Barash's Clinical Anesthesia 9e, pp. 1498–1500, 1805–1806, 2526 | Roberts & Hedges' Clinical Procedures in Emergency Medicine, p. 324

Various Doses of Rocuronium

Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Finding Sources
Reading File
Finding Sources
I now have comprehensive data from all major sources. Here is the complete synthesis:

Rocuronium — Doses by Indication

Rocuronium is an intermediate-acting, non-depolarizing aminosteroid neuromuscular blocking agent. Its low potency relative to other steroidal NMBDs is leveraged to achieve rapid onset. ED95 = 0.3 mg/kg (adults); approximately 0.4 mg/kg in children.

1. Intubation Doses

IndicationDose (mg/kg)OnsetClinical DurationNotes
Routine intubation0.45–0.6 mg/kg IV1.5–3 min35–75 minStandard: 2× ED95 (0.6 mg/kg)
Low-dose intubation0.45–0.5 mg/kg IV~1.5 min at larynxShorterUsed when faster recovery preferred; satisfactory conditions if laryngoscopy delayed 75–90 s
RSI (Rapid Sequence Intubation)0.9–1.2 mg/kg IV60–90 seconds~70–110 min (doubled)Equivalent to succinylcholine for RSI; 4× ED95 at 1.2 mg/kg
RSI — Pediatric1.2 mg/kg IV~60 sSimilar prolongationRecommended for full-stomach RSI in children
Increasing dose from 0.6 → 1.2 mg/kg shortens onset from ~89 s to ~55 s, but doubles clinical duration from ~37 min to ~73 min.

2. Maintenance Doses

MethodDoseTiming
Intermittent IV bolus0.1–0.2 mg/kgQ20–30 min PRN (when T1 returns to 25% of control)
Maintenance bolus (adults, general)0.15 mg/kgGuided by nerve stimulator
Continuous IV infusion5–12 mcg/kg/minAdjust to maintain desired block level
Infusion (Harriet Lane — adults)10–12 mcg/kg/min (range 4–16)Reduce by 30–50% at 45–60 min after intubating dose with inhalational agents

3. Pediatric Doses

Age GroupIntubating DoseMaintenance BolusMaintenance Infusion
Infant0.5 mg/kg IVQ20–30 min PRN
Child (3 mo – 14 yr)0.6 mg/kg IV0.075–0.125 mg/kg Q20–30 min PRN7–12 mcg/kg/min
RSI (pediatric, any age)1.2 mg/kg IV
Peak effect: 0.5–1 min in children | 1–3.7 min in adults
Duration: 30–40 min in children | 20–94 min in adults

4. Intramuscular Route (No IV Access)

PopulationIM DoseOnset
Infants1 mg/kg IM3–6 min
Children2 mg/kg IM3–6 min
Deltoid injection has faster onset than quadriceps injection.

5. Precurarization (Defasciculation Prior to Succinylcholine)

DosePurposeOnset
0.1 mg/kg IVReduces succinylcholine-induced fasciculations and post-op myalgias~90 seconds

6. Special Dosing Contexts

ContextDose Adjustment
Post-succinylcholine intubation (NMB maintenance needed)Use half the intubating dose = 0.3 mg/kg (1× ED95 sufficient)
Subsequent maintenance after intubating dose10–25% of intubating dose (0.05–0.15 mg/kg) to re-establish block
With volatile inhalational agentsReduce infusion by 30–50% (potentiation)
Elderly patientsProlonged duration — reduced hepatic mass; use with caution
Hepatic failureProlonged — larger Vd initially; longer elimination; reduced maintenance required
Renal failureGenerally usable; monitor with nerve stimulator
Obese patientsUse actual body weight for dose calculation

7. Comparative Table (Nondepolarizing Relaxants — Morgan & Mikhail Table 11-6)

DrugED₅₀ (mg/kg)Intubation Dose (mg/kg)Onset (min)Duration (min)Maintenance Bolus (mg/kg)Infusion (mcg/kg/min)
Rocuronium0.30.81.535–750.159–12
Vecuronium0.050.122.0–3.045–900.011–2
Atracurium0.20.52.5–3.030–450.15–12
Cisatracurium0.050.22.0–3.040–750.021–2
Pancuronium0.070.122.0–3.060–1200.01

Key Clinical Notes

  • Reversal: Sugammadex is the preferred reversal agent, enabling rapid reversal even of dense 1.2 mg/kg blocks. Neostigmine/glycopyrrolate can be used for moderate blockade once spontaneous recovery is present.
  • Avoid mixing NMBDs: Combining different NMBDs may produce unpredictable, markedly prolonged blockade.
  • Monitoring: Always use a peripheral nerve stimulator (train-of-four) to guide dosing and confirm recovery (TOF ratio ≥ 0.9 before extubation).
  • No active metabolites: Safer than vecuronium for prolonged ICU infusions.

Sources: Morgan & Mikhail's Clinical Anesthesiology 7e, pp. 390, 403 | Miller's Anesthesia 10e, pp. 3281–3284, 3318–3319 | Barash's Clinical Anesthesia 9e, pp. 1615–1616 | Harriet Lane Handbook 23e, pp. (Rocuronium entry)
This is a shared conversation. Sign in to Orris to start your own chat.